Measuring the effects of ketamine on mGluR5 using [ 18 F]FPEB and PET
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The metabotropic glutamate receptor 5 (mGluR5) is a promising treatment target for psychiatric disorders due to its modulatory effects on glutamate transmission. Using [ 11 C]ABP688, we previously showed that the rapidly acting antidepressant ketamine decreases mGluR5 availability. The mGluR5 radioligand [ 18 F]FPEB offers key advantages over [ 11 C]ABP688; however, its suitability for drug challenge studies is unknown. We evaluated whether [ 18 F]FPEB can be used to capture ketamine-induced effects on mGluR5. Seven healthy subjects participated in three [ 18 F]FPEB scans: a baseline, a same-day post-ketamine, and a 24-h post-ketamine scan. The outcome measure was V T / f P , obtained using a two-tissue compartment model and a metabolite-corrected arterial input function. Dissociative symptoms, heart rate and blood pressure increased following ketamine infusion. [ 18 F]FPEB V T / f P decreased by 9% across the cortex after ketamine infusion, with minimal difference between baseline and 24-h scans. Compared to our previous work using [ 11 C]ABP688, the magnitude of the ketamine-induced change in mGluR5 was smaller using [ 18 F]FPEB; however, effect sizes were similar for the same-day post-ketamine vs. baseline scan (Cohen’s d = 0.75 for [ 18 F]FPEB and 0.88 for [ 11 C]ABP688). [ 18 F]FPEB is therefore able to capture some of the effects of ketamine on mGluR5, but [ 11 C]ABP688 appears to be more suitable in drug challenge paradigms designed to probe glutamate transmission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, S-ketamine has been shown to induce a decrease in mGluR5 availability both in healthy and MDD subjects using PET (Esterlis et al., 2018; Holmes et al., 2020; Deschwanden et al., 2011).”
From A single subanaesthetic dose of the rapid-acting antidepressant S-ketamine raises presynaptic SV2A density in limbic regions of the Wistar Kyoto rat model of depression (2024) · cites this paper as Holmes et al., 2020
In the citing paper
“Studies have also shown alterations of the postsynaptic receptor mGluR5 within MDD and other psychiatric disorders (Abdallah et al., 2017; Esterlis et al., 2018; Holmes et al., 2020; Deschwanden et al., 2011).”
From A single subanaesthetic dose of the rapid-acting antidepressant S-ketamine raises presynaptic SV2A density in limbic regions of the Wistar Kyoto rat model of depression (2024) · cites this paper as Holmes et al., 2020
In the citing paper
“Human PET studies, as well as a postmortem Western blotting study, have found S-ketamine to reduce mGluR5 levels in both healthy and depressed subjects laying the basis for our hypothesis (Esterlis et al., 2018; Holmes et al., 2020; Deschwanden et al., 2011).”
From A single subanaesthetic dose of the rapid-acting antidepressant S-ketamine raises presynaptic SV2A density in limbic regions of the Wistar Kyoto rat model of depression (2024) · cites this paper as Holmes et al., 2020
In the citing paper
“Esterlis et al. reported reduced mGluR5 availability both immediately after and 24 h after ketamine administration in both MDD patients and healthy controls whereas Holmes et al. found reduced mGluR5 availability immediately after ketamine administration in healthy volunteers.”
From A single subanaesthetic dose of the rapid-acting antidepressant S-ketamine raises presynaptic SV2A density in limbic regions of the Wistar Kyoto rat model of depression (2024) · cites this paper as Holmes et al., 2020
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Nonrigid registration using free-form deformations: application to breast mr images
Rueckert, D., Sonoda, L. I., Hayes, C., Hill, D. L. G., Leach, M. O., & Hawkes, D. J. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.796284 · Cited by 5,265 · cited 1×
“5) and nonlinear transforms.(41,42) Regions of interest in the major cortical lobes – frontal, parietal, occipital and temporal were defined using the automated anatomical labeling template(43) for SPM2, and the aforementioned coregistration transforms.”
MethodKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“5mg/kg over 40min dose to enhance statistical power by inducing a larger glutamate surge as suggested by prior ketamine studies.(39,40) Both dosing regimens are similar in that they result in comparable changes in cognition and perception and do not cause the anesthetic effect.”
BackgroundSelf-citationMetabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
Niswender, C. M., & Conn, P. J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145533 · Cited by 1,892 · cited 1×
“The metabotropic glutamate receptor subtype 5 (mGluR5) is a G-protein coupled receptor that has important modulatory effects on glutamate transmission and is widely expressed throughout the brain.(7) Emerging evidence suggests that mGluR5 plays a key role in a range of psychiatric disorders,(8) including depression(9,…”
BackgroundSleep and circadian rhythm disruption in psychiatric and neurodegenerative disease
Wulff, K., Gatti, S., Wettstein, J. G., & Foster, R. G. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2868 · Cited by 1,055
Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins
Tu, J. C., Xiao, B., Naisbitt, S., Yuan, J. P., Petralia, R. S., Brakeman, P., Doan, A., Aakalu, V. K., Lanahan, A. A., Sheng, M., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80810-7 · Cited by 1,050 · cited 1×
“Indeed, ketamine is thought to have downstream effects on the activity of mGluR5, which is structurally linked to the NMDA receptor.(16) Using the radioligand [(11)C] ABP688, a negative allosteric modulator (NAM) of mGluR5, we previously showed that ketamine administration in humans was associated with reductions in a…”
Background
Research works printed but not linked: 6
- Abdallah CG, 2017, Biolog Psychiatry, 2, 449
- Leurquin-Sterk G, 2016, J Nucl Med, 57, 15
- McNair DM., 1971, Manual profile of mood states
- Papademetris X, 2001, Med Image Comput Comput Assist Interv, 3216, 763
- Berry SA, 1996, Mol Pharmacol, 50, 306
- 10.1177/0271678X16673646 · DOI · Paper page
Cited by
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“The paradigm builds on evidence that glutamate released by ketamine can reduce ligand ( 11 C-ABP688, 18 F-FPEB) binding to mGluR5 in two ways, through direct competition of glutamate and the PET ligand and by stimulating mGluR5 internalization [121].”
BackgroundSelf-citationImaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
Self-citationKrystal, J. H., Kaye, A. P., Jefferson, S., Girgenti, M. J., Wilkinson, S. T., Sanacora, G., & Esterlis, I. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305772120 · Cited by 90
Self-citationA Review of Molecular Imaging of Glutamate Receptors
Kim, J., Marton, J., Ametamey, S. M., & Cumming, P. D. (2020) · Molecules · doi:10.3390/molecules25204749 · Cited by 68
Holmes, S. E., Asch, R. H., Davis, M. T., DellaGioia, N., Pashankar, N., Gallezot, J.-D., Nabulsi, N., Matuskey, D., Sanacora, G., Carson, R. E., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.018 · Cited by 27
Self-citation
Metadata
- Authors
- Holmes, S. E., Gallezot, J.-D., Davis, M. T., DellaGioia, N., Matuskey, D., Nabulsi, N., Krystal, J. H., Javitch, J. A., DeLorenzo, C., Carson, R. E., & Esterlis, I.
- Affiliations
- Yale University (US)
- New York State Psychiatric Institute (US)
- Stony Brook University (US)
- Corresponding author
- Holmes, Sophie E
- ORCID
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2019-11-19
- Volume
- 40
- Issue
- 11
- Pages
- 2254-2264
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- PMC
- PMC7585925
- OpenAlex
- W2991178211
- Cited by
- 24
- References
- 63
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 1
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cerebral Blood Flow & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Institute of Mental Health (L30 MH120754, K08MH117351, R01MH104459)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine, metabotropic glutamate receptor 5, [18F]FPEB, [11C]ABP688, PET radiotracer, drug challenge, receptor availability, glutamatergic neurotransmission, dissociative symptoms, cerebral blood flow, two-tissue compartment model
- MeSH terms
- Adult, Biological Transport, Carbon Radioisotopes, Female, Humans, Ketamine, Magnetic Resonance Imaging, Male, Oximes, Pyridines, Sex Factors, Glutamic Acid, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography, Young Adult, Healthy Volunteers, Receptor, Metabotropic Glutamate 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measuring the effects of ketamine on mGluR5 using [ 18 F]FPEB and PET. https://app.cochat.ai/papers/10.1177/0271678x19886316
- The paper
- Holmes, S. E., Gallezot, J.-D., Davis, M. T., DellaGioia, N., Matuskey, D., Nabulsi, N., Krystal, J. H., Javitch, J. A., DeLorenzo, C., Carson, R. E., & Esterlis, I. (2020). Measuring the effects of ketamine on mGluR5 using [ 18 F]FPEB and PET. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1177/0271678x19886316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.